Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-570511
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-570511 is a non-steroidal selective androgen receptor modulator (SARM) developed by Bristol Myers Squibb. It was designed to selectively bind to the androgen receptor with high affinity, aiming to promote anabolic effects in muscle and bone while minimizing androgenic effects on tissues like the prostate and sebaceous glands. The compound has been investigated for the treatment of conditions involving muscle loss, such as sarcopenia and cancer cachexia, as well as for osteoporosis. Although it progressed into early clinical trials, the development program was eventually discontinued by the sponsor.
- Other names
- BMS 570511BMS570511BMS-570511
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on BMS-570511.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-570511.